Tokyo, Aug. 25 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062668) titled 'Effectiveness of Brivaracetam Used as the First Anti-Seizure Medication in Routine Clinical Practice for Japanese Patients with Epilepsy' on Aug. 25.
Study Type:
Observational
Primary Sponsor:
Institute - UCB Biopharma SRL
Condition:
Condition - Epilepsy
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the effectiveness of brivaracetam initial monotherapy in adult patients with focal onset (partial onset) seizures after brivaracetam treatment initiation for at least 12 months.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Ag...